Other languages MAIA Biotechnology, Inc.

Equities

MAIA

US5526411021

Market Closed - Nyse Other stock markets 16:00:00 2024-05-20 EDT			5-day change	1st Jan Change
3.41 ^USD	+3.02%		+11.80%	+191.45%

04-26	Maia Biotechnology Insider Bought Shares Worth $299,409, According to a Recent SEC Filing	MT
04-22	MAIA Biotechnology, Inc. announced that it expects to receive $0.664994 million in funding	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Maia Biotechnology Insider Bought Shares Worth $299,409, According to a Recent SEC Filing	04-26
MAIA Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-21
MAIA Biotechnology, Inc. Appoints Saadettin Kilickap to its Scientific Advisory Board	03-21
MAIA Biotechnology Announces Strong Efficacy of THIO as Third-Line Treatment for Non-Small Cell Lung Cancer Patients	03-08
MAIA Biotechnology, Inc. Announces Positive Efficacy Data for Third-Line Treatment in its Phase 2 THIO-101 Clinical Trial Evaluating THIO Sequenced with CPI Cemiplimab in Advanced NSCLC	03-06
MAIA Biotechnology, Inc. Appoints Remus Vezan to its Scientific Advisory Board	02-27
MAIA Biotechnology, Inc. Completes Enrollment in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer	02-22
MAIA Biotechnology, Inc. Announces Publication in Nature Communications on Positive Effects of THIO for Potential Treatment of Small Cell Lung Cancer	02-07
Maia Biotechnology, Inc. Announces Publication of International Pct Patent Application Covering Anticancer Telomere-Targeting Compounds	01-24
MAIA Biotechnology, Inc. Provides Positive Phase 2 Clinical Updates for Lead Anticancer Agent and Outlines Targeted Milestones for 2024	01-17
Top Premarket Decliners	01-12
MAIA Biotechnology, Inc. Announces Dose Selection in Thio-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer	12-19
MAIA Biotechnology Closes $4 Million Direct Offering	11-17
Top Midday Decliners	11-15
FDA Grants Orphan Drug Designation to MAIA Biotechnology for THIO as a Treatment for Glioblastoma	11-13
MAIA Biotechnology Says Glioblastoma Treatment Gets Orphan-Drug Designation From US FDA	11-10
MAIA Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-07
MAIA Biotechnology, Inc. Announces 100% Disease Control in Second-Line Non-Small Cell Lung Cancer Demonstrating Impressive Positive Preliminary Efficacy Data for Ongoing THIO-101 Phase 2 Trial	23-10-24
MAIA Biotechnology, Inc. Reveals New Data Showing THIO's Potent Anticancer Activity in Aggressive Pediatric Brain Cancer	23-10-12
Sector Update: Health Care Stocks Advancing Late Tuesday Afternoon	23-10-10

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages MAIA Biotechnology, Inc.

Equities

MAIA

US5526411021

Other languages

Filters